⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ANAB News
AnaptysBio, Inc. Common Stock
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
globenewswire.com
ANAB
GSK
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
globenewswire.com
ANAB
Anaptys Announces Participation in November Investor Conferences
globenewswire.com
ANAB
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
ANAB
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
globenewswire.com
ANAB
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
globenewswire.com
ANAB
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
globenewswire.com
ANAB
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
globenewswire.com
ANAB